Repligen (NASDAQ:RGEN – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Profitability
This table compares Repligen and iSpecimen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | -1.47% | 5.49% | 3.93% |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Repligen and iSpecimen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 1 | 3 | 12 | 2 | 2.83 |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
Repligen currently has a consensus price target of $178.57, suggesting a potential upside of 9.70%. Given Repligen’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Repligen is more favorable than iSpecimen.
Insider and Institutional Ownership
97.6% of Repligen shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Repligen and iSpecimen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $738.26 million | 14.09 | $48.89 million | ($0.21) | -775.14 |
| iSpecimen | $1.93 million | 0.79 | -$10.49 million | ($56.44) | -0.01 |
Repligen has higher revenue and earnings than iSpecimen. Repligen is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
Summary
Repligen beats iSpecimen on 12 of the 14 factors compared between the two stocks.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
About iSpecimen
iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
